Tech Support


This line is for technical support.
For General Enquiries please click General Contact

US East Coast Immuno-Oncology Xchange

May 15, 2019

Targeted Immunotherapies Track

Session Moderation

Dr Rajendra Kumari, Global Head of Scientific Communications

Time: 10:50-11:50am

Translational Research Topic: Relevance of current animal models for translational drug discovery in immuno-oncology

  • What are the advantages and limitations of syngeneic models
  • Utility of humanized models (PBMC engrafted versus CD34 HSC engrafted)
  • What are the next gen models for combination therapies: GEMMs
  • What is more important: efficacy or PD to move a drug discovery program forward?
Dr Rajendra Kumari


Effect of immune cell depletion on response to anti-PD-1 treatment in syngeneic models

Time: 14:30-15:00pm

Explore how different immune cell lineages impact anti-PD-1 response, through the depletion of various immune cell subpopulations in MC38, CT-26, and Hepa 1-6 murine syngeneic models when treated with PD-1 antibody.


Arrange a Meeting

Your privacy is important to us.
We'll never share your information.